CBD-dominant extract (33:1) in children/adolescents with ASD

Introduction and clinical context

The study CBD-dominant extract (33:1) in children/adolescents with ASD (PMC · 2024) is part of the scientific research on the use of cannabinoids in neuro and dementia.

Cannabinoids are studied in various neurological conditions — Parkinson's disease, dementias and Tourette syndrome, among others. The interest comes from the anti-inflammatory and neuromodulatory properties of the endocannabinoid system. In dementia, part of the research focuses on managing behavioral symptoms, such as agitation and aggression. The evidence is still heterogeneous and, in elderly and frail populations, requires redoubled caution regarding interactions and adverse effects.

Understanding what science shows about the use of cannabinoids in neuro and dementia helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. Observational study on neurobehavioral management in autism spectrum disorder. As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

In neurological disorders, the interest derives from the neuromodulatory and anti-inflammatory action of the endocannabinoid system, with CB1 receptors abundant in the central nervous system. In dementia and Parkinson's, an effect is sought on symptoms such as agitation, sleep and pain. Safety is a priority, especially in the elderly: sedation, dizziness, hypotension and fall risk, in addition to interactions from polypharmacy. THC's psychoactive effects require caution in conditions with cognitive impairment. Low doses, slow titration and close monitoring are essential.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PMC · 2024). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis treat Parkinson's or dementia?

The research is exploratory and focuses on symptoms (sleep, pain, agitation); there is no cure, and use requires follow-up.

Does cannabis help in Tourette syndrome?

Reviews discuss the potential of cannabinoids in reducing tics, but the evidence is still limited.